Inovio Pharmaceuticals (NASDAQ:INO) Announces Quarterly Earnings Results

Inovio Pharmaceuticals (NASDAQ:INO) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.18, Zacks reports. The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.03 million.

Inovio Pharmaceuticals Price Performance

Shares of INO opened at $1.96 on Thursday. The business’s 50-day moving average is $2.04 and its 200-day moving average is $3.76. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75. The company has a market capitalization of $51.16 million, a price-to-earnings ratio of -0.93 and a beta of 0.92.

Analyst Ratings Changes

Several analysts have issued reports on INO shares. Royal Bank of Canada cut their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a report on Wednesday. JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $12.20.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.